Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05699135 Terminated - Bladder Cancer Clinical Trials

A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

Start date: March 9, 2023
Phase:
Study type: Observational

The purpose of this study is to learn about the safety and effects of the study medicine (called avelumab) for the treatment of advanced bladder cancer. This study is including participants who: - Participated in the Canadian avelumab patient support program - Have been diagnosed with advanced bladder cancer - Have been treated with platinum-based chemotherapy without their disease progressing All participants in this study have previously received avelumab first-line maintenance for the treatment of their advanced bladder cancer. Pfizer will examine the experiences of people receiving the study medicine. This will help determine the efficacy and safety of the study medicine for the treatment of bladder cancer.

NCT ID: NCT05698992 Recruiting - Gastric Cancer Clinical Trials

Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer

Start date: February 27, 2023
Phase:
Study type: Observational [Patient Registry]

This study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.

NCT ID: NCT05698953 Completed - Reiki Clinical Trials

The Effect of Reiki Therapy in Pediatric Oncology Patients

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The study was conducted based on randomized controlled experimental design with double-blind, pre-test-post-test to determine the effect of Reiki applied to pediatric oncology patients aged 5-7 years on pain, vital signs, oxygen saturation (SpO2) and quality of life. While the population of the study consisted of oncology patients aged 5-7 years who were hospitalized in the pediatric oncology services between December 2020 and November 2021, the sample consisted of 66 children diagnosed with leukemia who met the sample selection criteria. The research consists of 3 groups. These groups are Reiki group (n=22), Placebo group (n=22), control group (n=22). The data are collected using Introductory Information Form, Wong-Baker FACES Pain Scale (W-BPS), Vital Signs Follow-up Form, The Pediatric Quality of Life Inventory (PedsQL) 3.0 Cancer Module Child and Parent Form. Reiki was applied to the Reiki group for 20-30 minutes for three consecutive days and Placebo was applied to the sham Reiki group by an independent nurse during the same application period. The children in the control group were like the routine of the ward.

NCT ID: NCT05698667 Completed - Oropharynx Cancer Clinical Trials

Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The aim of the study was to examine the detection rate and tumor size evaluation in patients with suspected oropharynx cancer using a new technique with transoral ultrasound of the oropharynx. The new technique was compared to Magnetic Resonance Imaging (MRI). The study investigators included patients referred to a tertiary head & neck cancer center in Copenhagen, Denmark, with suspicion of oropharynx cancer. Patients supplied written informed consent and were included and ultrasound scanned with local anesthesia in the outpatient clinic. Blinded assessment of MRI's was performed for tumor detection and compared to ultrasound with the reference standard being histopathology biopsy results.

NCT ID: NCT05697874 Recruiting - BCOR ITD Sarcoma Clinical Trials

International Rare Brain Tumor Registry

IRBTR
Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed with rare brain tumors.

NCT ID: NCT05694364 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Start date: January 25, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC) malignancies.

NCT ID: NCT05693844 Recruiting - Clinical trials for Advanced or Metastatic Solid Tumors

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

Start date: January 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

In preclinical study, investigators have demonstrated that the newly developed pan-T booster (harbouring CD40 agonist and one T cell costimulator agonist) co-expressing MSLN CAR T cell possess more powerful antitumor activity than previously reported MSLN-CAR T cells. In this clinical trial, enrolled patients receive an initial dose of pan-T booster co-expressing MSLN CAR T cells at 1×10^6 cells/kg based on the basic principle of dose escalation design, in order to evaluate the safety, feasibility, pharmacokinetics/pharmacodynamics, and efficacy of pan-T booster co-expressing MSLN CAR T cell in vivo.

NCT ID: NCT05692466 Recruiting - Clinical trials for Stage IV Solid Tumors

Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")

DINOSAur
Start date: February 1, 2023
Phase:
Study type: Observational [Patient Registry]

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

NCT ID: NCT05692102 Not yet recruiting - Gynecologic Cancer Clinical Trials

Quality of Life After Gynacological Malignancies

Start date: June 2023
Phase:
Study type: Observational

Evaluate quality of life after gynaecological malignancies diagnosis and treatment

NCT ID: NCT05691816 Completed - Pediatric Oncology Clinical Trials

The Experience of the Child With Cancer When Port à Cath Needle : Child's Speech

ELEAPort
Start date: January 1, 2022
Phase:
Study type: Observational

This qualitative research refers to the descriptive phenomenological method of Hurssel which allows an analysis of the experience and an understanding of the phenomenon. Semi-structured interviews are carried out with 10 children followed for cancer in 3 pediatric hemato-oncology departments. The children interviewed are aged 6 to 12 and can be with their parents. A thematic analysis approach is used to analyze the data of this research.